Unicycive Therapeutics (UNCY) Current Assets (2020 - 2026)
Unicycive Therapeutics' (UNCY) quarterly Current Assets came in at $63.5 million in Q1 2026, up 132.37% YoY from $27.3 million in Q1 2025, and up 29.79% on a QoQ basis from $49.0 million in Q4 2025.
Unicycive Therapeutics (UNCY) Current Assets (2020 - 2026) Analysis & Trends
Unicycive Therapeutics (UNCY) has 7 years of Current Assets data on file, last reported at $63.5 million in Q1 2026.
- Quarterly Current Assets rose 132.37% year-over-year to $63.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $63.5 million (up 132.37% YoY) and the FY2025 annual result came in at $49.0 million, up 58.2% from the prior year.
- Current Assets improved to $63.5 million in Q1 2026, from $49.0 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $63.5 million in Q1 2026 to a low of $2.6 million in Q4 2022.
- A 5-year average of $29.7 million and a median of $27.3 million in 2025 frame the typical range for Current Assets.
- The widest YoY moves for Current Assets: up 1275.68% in 2022, down 85.64% in 2022.
- Tracing UNCY's Current Assets over 5 years: stood at $2.6 million in 2022, then jumped by 406.77% to $13.4 million in 2023, then jumped by 130.97% to $30.9 million in 2024, then jumped by 58.2% to $49.0 million in 2025, then climbed by 29.79% to $63.5 million in 2026.
- The last three Current Assets figures came in at $63.5 million (Q1 2026), $49.0 million (Q4 2025), and $50.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.76 Bn |
| 10 | Unicycive Therapeutics | 151.01 Mn | 151.01 Mn | - | 71.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 71.32 Mn |
| Mar 31, 2026 | 63.55 Mn |
| Dec 31, 2025 | 48.96 Mn |
| Sep 30, 2025 | 50.29 Mn |
| Jun 30, 2025 | 29.53 Mn |
| Mar 31, 2025 | 27.35 Mn |
| Dec 31, 2024 | 30.95 Mn |
| Sep 30, 2024 | 37.74 Mn |
| Jun 30, 2024 | 44.05 Mn |
| Mar 31, 2024 | 51.68 Mn |
| Dec 31, 2023 | 13.40 Mn |
| Sep 30, 2023 | 18.57 Mn |
| Jun 30, 2023 | 21.93 Mn |
| Mar 31, 2023 | 26.18 Mn |
| Dec 31, 2022 | 2.64 Mn |
| Sep 30, 2022 | 9.96 Mn |
| Jun 30, 2022 | 12.56 Mn |
| Mar 31, 2022 | 15.46 Mn |
| Dec 31, 2021 | 18.41 Mn |
| Sep 30, 2021 | 19.78 Mn |